Home

Thomas Andrew Crockett

CIK 1690920 · CEO · last filed 2024-02-21

Thomas Andrew Crockett is a CEO who has filed 41 SEC Form 4 insider transactions across 1 company since 2016. The most recent filing, for KALV, was dated Feb 21, 2024. Across all open-market trades the lifetime net is −$5.5M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

41

Lifetime Open-Market Net

-$5.47M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KalVista Pharmaceuticals, Inc. (KALV) Delisted CEO 236,091 $27.00 $6.37M -$5.47M 40 2024-02-21

Recent Filings

41 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-02-21 KalVista Pharmaceuticals, Inc. (KALV) Delisted Mixed +29,527 -$351.3K EDGAR
2024-02-16 KalVista Pharmaceuticals, Inc. (KALV) Delisted Sell (S) −58,356 -$875.9K EDGAR
2024-02-13 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) +122,500 $0 EDGAR
2024-02-05 KalVista Pharmaceuticals, Inc. (KALV) Delisted Sell (S) −10,000 -$162.2K EDGAR
2023-12-28 KalVista Pharmaceuticals, Inc. (KALV) Delisted Sell (S) −30,000 -$360.5K EDGAR
2023-12-27 KalVista Pharmaceuticals, Inc. (KALV) Delisted Notice (144) −40,000 -$480.0K EDGAR
2023-11-21 KalVista Pharmaceuticals, Inc. (KALV) Delisted Mixed +18,776 -$121.9K EDGAR
2023-11-01 KalVista Pharmaceuticals, Inc. (KALV) Delisted Gift (G) −8,000 $0 EDGAR
2023-08-21 KalVista Pharmaceuticals, Inc. (KALV) Delisted Mixed +18,706 -$159.6K EDGAR
2023-05-22 KalVista Pharmaceuticals, Inc. (KALV) Delisted Exer (M) — $0 EDGAR
Showing 1–10 of 41
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.